Medicinal Chemistry Strategies for the Development of CD73 Inhibitors in Cancer Immunotherapy
Medicinal Research Reviews · 2026
DOI: 10.1002/med.70029 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, 2026. Verfasst von Meng Cui und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Trial Ward, Clinical Trial and Conversion Center, Shengjing Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: 5'-Nucleotidase, Neoplasms, Immunotherapy, Chemistry, Pharmaceutical. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 93 Literaturangaben.
Abstract (Originalsprache)
CD73, a membrane‐bound ecto‐5′‐nucleotidase, catalyzes the extracellular conversion of adenosine monophosphate into immunosuppressive adenosine. Functioning as an emerging immune checkpoint, CD73 is frequently upregulated across numerous tumor types, contributing to the accumulation of adenosine within the tumor microenvironment and promoting immune evasion. Intensive efforts have led to the discovery of diverse CD73 inhibitors, which show strong potential in cancer immunotherapy. To date, around eighteen candidates targeting CD73 have entered clinical evaluation, many exhibiting encouraging efficacy in combination regimens for solid tumors. This review provides an overview of the biological functions of CD73 in tumor‐induced immunosuppression and highlights the medicinal chemistry strategies employed in the development of small‐molecule CD73 inhibitors since 2018. Additionally, the challenges in drug design and future directions are also discussed to enhance the clinical applicability of CD73‐targeted therapies in cancer treatment. We believe that this review will offer valuable insights to guide the rational design of next‐generation CD73 inhibitors for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Trial Ward, Clinical Trial and Conversion Center, Shengjing Hospital of China Medical University, Shenyang, China.
- Department of Interventional Radiology, Shengjing Hospital of China Medical University, Shenyang, China.
- Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
- Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
ORCID-Profile: Xiaofei Sun
Zitieren
APA
Cui, M., Ma, S., Huang, Z., Zhang, D., Sun, X., & You, Y. (2026). Medicinal Chemistry Strategies for the Development of CD73 Inhibitors in Cancer Immunotherapy. Medicinal Research Reviews. https://doi.org/10.1002/med.70029
Vancouver
Cui M, Ma S, Huang Z, Zhang D, Sun X, You Y. Medicinal Chemistry Strategies for the Development of CD73 Inhibitors in Cancer Immunotherapy. Medicinal Research Reviews. 2026. doi:10.1002/med.70029
BibTeX
@article{Cui2026,
author = {Cui, Meng and Ma, Shaowei and Huang, Zhe and Zhang, Danye and Sun, Xiaofei and You, Yue},
title = {Medicinal Chemistry Strategies for the Development of CD73 Inhibitors in Cancer Immunotherapy},
journal = {Medicinal Research Reviews},
year = {2026},
doi = {10.1002/med.70029}
}
EUVIMED